Latest other assets for CLVS: $100M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2022), CLVS shows a other assets of $100M. That compares with $130M in the prior-year period — down 17.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CLVS's other assets is now $100M (was $130M) — a 17.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Clovis Oncology is outperforming or lagging.
Tracking CLVS's other assets over time shows whether Clovis Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $100M That compares with $130M in the prior-year period — down 17.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other assets page, Stockcircle has Clovis Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $100M) with ownership activity and broader fundamentals.
Clovis Oncology's other assets is $100M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.